At $2M per shot, ICER says two new sickle cell gene therapies could be cost-effective
Gene therapies approved by the FDA have so far brought with them eye-popping prices of $2 million or more because of the extraordinary savings, sometimes over a lifetime, that can occur if the therapies prove safe, effective and durable.
In the case of the incoming sickle cell disease gene therapies from Vertex Pharmaceuticals and CRISPR Therapeutics, known as exagamglogene autotemcel or exa-cel, and bluebird bio’s lovotibeglogene autotemcel or lovo-cel, ICER said that for a price of about $2 million per potential shot, the therapies could be cost effective under some scenarios although “these gene therapies have an incremental cost effectiveness that is above commonly cited thresholds from the health care system perspective.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
